Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-438-2 | CAS number: 106-88-7
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 975
- Report date:
- 1975
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- 1,2-epoxybutane
- EC Number:
- 203-438-2
- EC Name:
- 1,2-epoxybutane
- Cas Number:
- 106-88-7
- Molecular formula:
- C4H8O
- IUPAC Name:
- oxolane
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BASF SE
- Age at study initiation: no data
- Weight at study initiation: The mean body weight of male animals was 206 g, the mean body weight of female animals was 174 g
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- The test substance was given as an emulsion in 0.5% aqueous CMC solution.
Observation period: 7 resp. 14 days - Doses:
- 100, 464, 681, 1000, 1210, 1470, 1780, 2150, 4640, 10000 µL/kg
- No. of animals per sex per dose:
- 5 and/or 10 (see mortality table)
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 7 resp. 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- no data
Results and discussion
Effect levelsopen allclose all
- Key result
- Sex:
- male/female
- Dose descriptor:
- approximate LD50
- Effect level:
- ca. 913 mg/kg bw
- Remarks on result:
- other: Calculated with density of 0.83 g/cm3
- Sex:
- male/female
- Dose descriptor:
- approximate LD50
- Effect level:
- ca. 1 100 other: µL/kg
- Remarks on result:
- other: original value
- Mortality:
- yes (see table below)
- Clinical signs:
- other: slight apathy, partially staggering, dyspnoea, diarrheic feces, exsiccosis, abdominal and lateral position
- Gross pathology:
- acute heart dilatation (both sides), acute congestive hyperemia, intra-abdominal adhesions of the stomach, thickened wall of the forestomach, partially formation of diverticulum
Any other information on results incl. tables
Mortality:
| Dose (µL/kg) | Concentration (%) | No. of animals | dead within | ||||
| 1 hour | 24 hours | 48 hours | 7 days | 14 days | |||
| 10000 | 35 | 5 males | 0/5 | 5/5 | 5/5 | 5/5 | |
| 5 females | 0/5 | 5/5 | 5/5 | 5/5 | |||
| 4640 | 35 | 5 males | 0/5 | 5/5 | 5/5 | 5/5 | |
| 5 females | 0/5 | 5/5 | 5/5 | 5/5 | |||
| 2150 | 30 | 10 males | 0/10 | 10/10 | 10/10 | 10/10 | |
| 10 females | 1/10 | 10/10 | 10/10 | 10/10 | |||
| 1780 | 15 | 5 males | 0/5 | 5/5 | 5/5 | 5/5 | |
| 5 females | 0/5 | 5/5 | 5/5 | 5/5 | |||
| 1470 | 15 | 10 males | 0/10 | 10/10 | 10/10 | 10/10 | |
| 10 females | 0/10 | 10/10 | 10/10 | 10/10 | |||
| 1210 | 15 | 5 males | 0/5 | 2/5 | 2/5 | 2/5 | |
| 5 females | 0/5 | 5/5 | 5/5 | 5/5 | |||
| 1000 | 15 | 5 males | 0/5 | 1/5 | 1/5 | 1/5 | |
| 5 females | 0/5 | 0/5 | 0/5 | 0/5 | |||
| 681 | 6 | 5 males | 0/5 | 0/5 | 0/5 | 0/5 | |
| 5 females | 0/5 | 0/5 | 0/5 | 0/5 | |||
| 464 | 6 | 5 males | 0/5 | 0/5 | 0/5 | 0/5 | |
| 5 females | 0/5 | 0/5 | 0/5 | 0/5 | |||
| 100 | 1.5 | 5 males | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| 5 females | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | ||
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
